

TRADE SECRET

Study Title

H-24921, H-26313, and H-26225: Evaluation of the Interference of the Test Substance in the Analysis of Rat Serum Lipids

AUTHOR: Denise Hoban, B.A, MLT (ASCP)

STUDY COMPLETED ON: October 13, 2004

TESTING FACILITY: E.I. du Pont de Nemours and Company
HaskellSM Laboratory for Health and Environmental Sciences
Elkton Road, P.O. Box 50
Newark, Delaware 19714-0050
U.S.A.

LABORATORY PROJECT ID: DuPont-15372

[REDACTED]
[REDACTED]

SPONSOR: E.I. du Pont de Nemours and Company
Wilmington, Delaware 19898
U.S.A.

CERTIFICATION

I, the undersigned, declare that this report provides an accurate evaluation of data obtained from this study.

Issued by Study Director: _____

Denise Hoban
Denise Hoban, B.A, MLT (ASCP)
Staff Medical Technologist and Supervisor

13 Oct 2004
Date

TABLE OF CONTENTS

	Page
CERTIFICATION	2
STUDY INFORMATION.....	4
SUMMARY.....	6
OBJECTIVE.....	7
EXPERIMENTAL DESIGN.....	7
MATERIALS AND METHODS	8
A. Test Substances	8
B. Phosphate Buffered Saline (PBS).....	8
C. Experimental Procedures.....	9
RESULTS AND DISCUSSION	12
A. Clinical Chemistry Analyses	12
CONCLUSIONS	12
RECORDS AND SAMPLE STORAGE	12
TABLES.....	13
TABLE 1 SUMMARY OF CLINICAL CHEMISTRY PARAMETERS FOR SERIAL DIUTIONS OF H-24921 IN PBS.....	15
TABLE 2 SUMMARY OF CLINICAL CHEMISTRY PARAMETERS FOR SERIAL DIUTIONS OF H-24921 IN SERUM	16
TABLE 3 SUMMARY OF CLINICAL CHEMISTRY PARAMETERS FOR SERIAL DIUTIONS OF H-26313 IN PBS.....	17
TABLE 4 SUMMARY OF CLINICAL CHEMISTRY PARAMETERS FOR SERIAL DIUTIONS OF H-26313 IN SERUM	18
TABLE 5 SUMMARY OF CLINICAL CHEMISTRY PARAMETERS FOR SERIAL DIUTIONS OF H-26225 IN PBS.....	19
TABLE 6 SUMMARY OF CLINICAL CHEMISTRY PARAMETERS FOR SERIAL DIUTIONS OF H-26225 IN SERUM	20
APPENDICES	21
APPENDIX A CLINICAL CHEMISTRY DATA	22

STUDY INFORMATION

9th Collective Nomenclature: Octanoic acid, pentadecafluoro-, ammonium salt

Synonyms/Codes: • Ammonium perfluorooctanoate

- C-8
- Perfluorooctanoate, ammonium salt
- PFOA
- H-24921

Haskell Number: 24921

CAS Registry Number: [REDACTED]

Composition: [REDACTED]

Purity: [REDACTED]

Physical Characteristics: White solid

Stability: The test substance appeared to be stable under the conditions of the study; no evidence of instability was observed.

STUDY INFORMATION (Continued)

Substance Tested: APFO [REDACTED]

Synonyms/Codes: • Ammonium perfluorooctanoate
[REDACTED]

Haskell Number: 26313

CAS Registry Number: [REDACTED]

Known Impurities: [REDACTED]

Physical Characteristics: Water white to slightly opaque liquid

Stability: The test substance appeared to be stable under the conditions of the study; no evidence of instability was observed.

Substance Tested: APFO [REDACTED]

Haskell Number: 26225

Known Impurities: [REDACTED]

Physical Characteristics: White solid

Stability: The test substance appeared to be stable under the conditions of the study; no evidence of instability was observed.

Study Initiated/Completed: July 29, 2004 / (see report cover page)

Experimental Start/Termination: July 29, 2004 / July 30, 2004

SUMMARY

The objective of this study was to evaluate whether or not the *in vitro* addition of H-24921, H-26313, and H-26225 to pooled normal fasted rat serum interfered with the determination of any of the following clinical pathology parameters: triglycerides, total cholesterol, high-density lipoprotein cholesterol, or non-high-density lipoprotein cholesterol.

The test substance was added to fresh phosphate buffered saline (PBS) or pooled normal rat serum. Subsequently, serial dilutions were performed. Dilutions in PBS and serum, and negative controls of PBS and serum, were analyzed for triglyceride, total cholesterol, HDL cholesterol, and non-HDL cholesterol.

Neither H-24921, H-26313, nor H-26225, at concentrations up to 720 $\mu\text{g/mL}$, interfered with the determination of concentration of triglycerides, total cholesterol, HDL cholesterol, or non-HDL cholesterol in phosphate-buffered saline or in pooled normal rat serum.

OBJECTIVE

The objective of this study was to evaluate whether or not the *in vitro* addition of H-24921, H-26313, or H-26225 to pooled normal fasted rat serum interfered with the determination of any of the following clinical pathology parameters: triglycerides, total cholesterol, high-density lipoprotein cholesterol, or non-high-density lipoprotein cholesterol.

EXPERIMENTAL DESIGN

The following experimental design was conducted for each of the 3 test substances. Negative control samples were analyzed for each part of the study.

Dilution	Concentration of Test Substance ($\mu\text{g/mL}$)	Pooled Normal Rat Serum	
		PBS √ (PBS Negative Control)	√ (Serum Negative Control)
1	0.0	√	√
2	720.0	√	√
4	360.0	√	√
5	180.0	√	√
6	90.0	√	√
7	45.0	√	√
8	22.5	√	√
9	11.3	√	√
10	5.6	√	√
11	2.8	√	√
12	1.4	√	√
13	0.7	√	√

MATERIALS AND METHODS

A. Test Substances

Test Substances: The test substances were assigned the following Haskell Laboratory numbers:

Part A: H-24921 for APFO [REDACTED]

Part B: H-26313 for APFO [REDACTED]

Part C: H-26225 for APFO [REDACTED] H-26225 is made by combining H-26203 and H-26204.

A: H-24921 [APFO [REDACTED]], a solid, was mixed with DMSO.

B: H-26313 [APFO [REDACTED]], a liquid, was mixed with DMSO.

C: H-26203 and H-26204, solids, were combined to form H-26225 [APFO [REDACTED]]. Stock solutions for the highest concentration were made with H-26203 and H-26204 using DMSO. The stock solutions were mixed together at a ratio of [REDACTED] resulting in the stock solution for H-26225.

Dilutions were not analyzed to verify concentration and stability

Purity/Assay: Confirmation of identity and purity of the test substance were conducted on a recent study, and were not conducted on this study.^(1,2)

Stock Concentration: 14,400 $\mu\text{g/mL}$ (or 14.4 mg/mL) in volumes of approximately 1 mL

Vehicle: dimethylsulfoxide (DMSO)

Storage Conditions: The test substances were stored at normal room temperature and humidity prior to preparation of the solutions.

B. Phosphate Buffered Saline (PBS)

Manufacturer: Fluka BioChemika

Expiration Date: April 2009

Lot Number: 

Physical State: clear, colorless liquid

Storage Conditions: normal room temperature and humidity

Known Contaminants: none

C. Experimental Procedures

Animal Care and Housing: Stock male Crl:CD[®](SD)IGS BR rats previously obtained from Charles River Laboratories, Inc were used in this study. The Crl:CD[®](SD)IGS BR male rat was selected because it was used in a previous study with these test substances.

All rats were housed in stainless steel, wire-mesh cages suspended above cage boards. Animal rooms were maintained at a temperature of $22 \pm 3^{\circ}\text{C}$ and a relative humidity of $50 \pm 20\%$. Animal rooms were artificially illuminated (fluorescent light) on an approximate 12-hour light/dark cycle.

All rats were provided tap water *ad libitum*. All rats were fed PMI[®] Nutrition International, LLC Certified Rodent LabDiet[®] 5002 except when fasted. Rats were fasted overnight prior to sample collection.

As specified in the Haskell Laboratory animal health and environmental monitoring program, the following procedures are performed periodically to ensure that contaminant levels are below those that would be expected to impact the scientific integrity of the study:

- Water samples are analyzed for total bacterial counts, and the presence of coliforms, lead, and other contaminants.
- Samples from freshly washed cages and cage racks are analyzed to ensure adequate sanitation by the cagewashers.

Certified animal feed is used, guaranteed by the manufacturer to meet specified nutritional requirements and not to exceed stated maximum concentrations of key contaminants, including specified heavy metals, aflatoxin, chlorinated hydrocarbons, and organophosphates. The presence of these contaminants below the maximum concentration stated by the manufacturer would not be expected to impact the integrity of the study.

The animal health and environmental monitoring program is administered by the attending laboratory animal veterinarian. Evaluation of these data did not indicate any conditions that affected the validity of the study.

- Blood Source and Collection Site:** Descending aorta or the abdominal *vena cava* from healthy fasted stock CrI:CD[®](SD)IGS BR rats approximately 8 weeks of age or older. Blood was collected while rats were under carbon dioxide anesthesia. After blood collection, rats were euthanized and discarded.
- Blood Handling:** Approximately 6-8 mL of whole blood was collected from each rat and placed into commercially available serum separator collection tubes. Blood was processed to serum after centrifugation at 2500 rpm for 15 minutes and pooled.
- PBS Negative Control:** PBS without test substance was tested as the PBS negative control.
- Serum Negative Control:** Rat serum (pooled) without test substance was used as the serum negative control.
- Addition of Test Substances to PBS or Serum:** For each part of the study, the test substance was added to fresh PBS or serum as follows: test substance at 14,400 $\mu\text{g/mL}$ was diluted 1:2 in both PBS and serum (concentrations of 7200 $\mu\text{g/mL}$). These working solutions were diluted using 1:10 dilutions to achieve concentrations of 720 $\mu\text{g/mL}$ in PBS or serum. Subsequently, serial dilutions were performed according to the Experimental Design. The test samples in PBS and in serum were prepared at approximately the same time. The test samples in PBS and in serum were gently mixed prior to incubation at room temperature.
- Incubation, Processing, and Analysis:** Test samples in PBS and serum, and negative controls were incubated at ambient temperature for approximately 10 minutes. Immediately after incubation, the samples were frozen at approximately -80°C in plastic tubes until the analysis was run (at least overnight, but not more than 3 days). Prior to analysis, the samples were thawed, placed on the Olympus AU 640 clinical chemistry analyzer and analyzed in triplicate (one tube analyzed 3 times) by standard procedures for the following parameters:

Triglyceride

Method: Enzymatic (lipases, kinase, oxidase, and peroxidase), with colorimetric detection (Olympus Diagnostics, CAT # OSR6116)

Total cholesterol

Method: enzymatic (esterase and oxidase), with colorimetric detection (Olympus Diagnostics, CAT # OSR6133)

High-density lipoprotein cholesterol (HDL)

Method: Accelerator Selective Detergent methodology, with colorimetric detection (Equal Diagnostics, CAT # 6121)

Non-high-density lipoprotein cholesterol (non-HDL)

Method: Calculated

Calculations: Mean values were calculated for the clinical chemistry parameters for all control and test samples.

Calculation of interference at each concentration of test substance was not conducted, because there was no interference detected.

RESULTS AND DISCUSSION

A. Clinical Chemistry Analyses

(Tables 1-6, Appendix A)

The values for the measured lipid concentrations did not change despite a thousand-fold change in test substance concentration. Therefore, the test substances did not have any effect on the measurement of triglycerides, total cholesterol, HDL cholesterol, and non-HDL cholesterol in pooled normal rat serum or in phosphate buffered saline.

CONCLUSIONS

Neither H-24921, H-26313, nor H-26225, at concentrations up to 720 $\mu\text{g/mL}$, interfered with the determination of concentration of triglycerides, total cholesterol, HDL cholesterol, or non-HDL cholesterol in phosphate-buffered saline or in pooled control rat serum.

RECORDS AND SAMPLE STORAGE

Specimens (if applicable), raw data, and the final report will be retained at Haskell Laboratory, Newark, Delaware, or at Iron Mountain Records Management, Wilmington, Delaware.

REFERENCES

1. DuPont Haskell Laboratory unpublished data, [REDACTED]
2. DuPont Haskell Laboratory unpublished data, [REDACTED]

TABLES

TABLES

EXPLANATORY NOTES

ABBREVIATIONS:

PBS - phosphate buffered saline
CHOL - cholesterol
TRIG - triglycerides
HDL - high-density lipoprotein cholesterol
non-HDL - non-high-density lipoprotein cholesterol

TABLE I

SUMMARY OF CLINICAL CHEMISTRY PARAMETERS FOR SERIAL DIUTIONS OF H-24921 IN PBS

NEGATIVE CONTROL		SERIAL DILUTIONS ($\mu\text{g/mL}$)										
		720	360	180	90	45	22.5	11.3	5.6	2.8	1.4	0.7
CHOL (mg/dL)	0	0	0	0	0	0	0	0	0	0	0	0
	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
TRIG (mg/dL)	0	0	0	0	0	0	0	0	0	0	0	0
	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
HDL (mg/dL)	0	0	0	0	0	0	0	0	0	0	0	0
	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
non-HDL (mg/dL)	0	0	0	0	0	0	0	0	0	0	0	0
	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00

Data arranged as: Mean
 Standard deviation

TABLE 2

SUMMARY OF CLINICAL CHEMISTRY PARAMETERS FOR SERIAL DIUTIONS OF H-24921 IN SERUM

	NEGATIVE CONTROL	SERIAL DILUTIONS ($\mu\text{g/mL}$)										
		720	360	180	90	45	22.5	11.3	5.6	2.8	1.4	0.7
CHOL (mg/dL)	54 0.00	51 0.58	53 0.58	53 0.00	54 0.00	54 0.58	55 2.00	57 3.06	55 1.00	54 0.00	54 0.00	54 1.00
TRIG (mg/dL)	48 0.58	46 0.58	48 0.58	49 0.58	49 0.00	49 0.00	50 1.53	49 0.58	49 1.00	49 0.00	49 0.00	49 0.58
HDL (mg/dL)	23 0.58	21 0.00	22 0.00	23 0.58	23 0.00	23 0.00	24 1.53	23 0.58	23 0.58	23 0.58	23 0.58	23 0.58
non-HDL (mg/dL)	31 0.58	30 0.58	31 0.58	30 0.58	31 0.00	31 0.58	31 0.58	33 3.21	32 0.58	31 0.58	31 0.58	31 0.58

Data arranged as: Mean
 Standard deviation

TABLE 3

SUMMARY OF CLINICAL CHEMISTRY PARAMETERS FOR SERIAL DIUTIONS OF H-26313 IN PBS

NEGATIVE		SERIAL DILUTIONS										
		(μg/mL)										
CONTROL	720	360	180	90	45	22.5	11.3	5.6	2.8	1.4	0.7	
CHOL (mg/dL)	0	0	0	0	0	0	0	0	0	0	0	
	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
TRIG (mg/dL)	0	0	0	0	0	0	0	0	0	0	0	
	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
HDL (mg/dL)	0	0	0	0	0	0	0	0	0	0	0	
	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	
non-HDL (mg/dL)	0	0	0	0	0	0	0	0	0	0	0	
	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	

Data arranged as:

Mean

Standard deviation

TABLE 4

SUMMARY OF CLINICAL CHEMISTRY PARAMETERS FOR SERIAL DILUTIONS OF H-26313 IN SERUM

	NEGATIVE CONTROL	SERIAL DILUTIONS ($\mu\text{g/mL}$)											
		720	360	180	90	45	22.5	11.3	5.6	2.8	1.4	0.7	
CHOL (mg/dL)	54 0.00	52 0.58	53 0.00	54 0.58	54 0.58	55 1.53	55 0.58	55 0.58	56 1.15	55 0.00	54 0.00	55 2.08	
TRIG (mg/dL)	49 0.58	47 0.58	48 0.00	48 0.00	49 0.58	49 1.00	49 1.73	49 0.00	49 0.58	49 0.58	49 0.58	50 1.15	
HDL (mg/dL)	23 0.58	21 0.00	22 0.00	23 0.00	23 0.00	23 0.58	24 0.58	23 0.58	23 0.58	23 0.58	23 0.00	24 0.58	
non-HDL (mg/dL)	31 0.58	31 0.58	31 0.00	31 0.58	31 0.58	31 1.15	32 0.58	31 0.58	32 0.58	32 0.58	31 0.00	32 1.53	

Data arranged as:

Mean

Standard deviation

Company Sanitized. Does not contain TSCA CBI

TABLE 5

SUMMARY OF CLINICAL CHEMISTRY PARAMETERS FOR SERIAL DIUTIONS OF H-26225 IN PBS

NEGATIVE CONTROL		SERIAL DILUTIONS ($\mu\text{g/mL}$)										
		720	360	180	90	45	22.5	11.3	5.6	2.8	1.4	0.7
CHOL (mg/dL)	0	0	0	0	0	0	0	0	0	0	0	0
	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
TRIG (mg/dL)	0	0	0	0	0	0	0	0	0	0	0	0
	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
HDL (mg/dL)	0	0	0	0	0	0	0	0	0	0	0	0
	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
non-HDL (mg/dL)	0	0	0	0	0	0	0	0	0	0	0	0
	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00

Data arranged as:

Mean

Standard deviation

TABLE 6

SUMMARY OF CLINICAL CHEMISTRY PARAMETERS FOR SERIAL DIUTIONS OF H-26225 IN SERUM

	NEGATIVE CONTROL	SERIAL DILUTIONS ($\mu\text{g/mL}$)											
		720	360	180	90	45	22.5	11.3	5.6	2.8	1.4	0.7	
CHOL (mg/dL)	54 0.00	51 0.58	53 0.00	54 0.58	54 0.00	54 0.58	54 0.58	55 1.15	54 0.58	55 1.15	54 0.58	54 0.58	
TRIG (mg/dL)	49 0.00	47 0.00	48 0.58	49 0.58	49 0.58	49 0.58	49 0.00	49 1.00	49 0.00	50 0.58	49 0.00	49 0.00	
HDL (mg/dL)	23 0.00	21 0.58	22 0.00	23 0.00	23 0.00	23 0.00	23 0.00	23 0.58	23 0.00	23 0.00	23 0.58	23 0.00	
non-HDL (mg/dL)	31 0.00	31 0.58	31 0.00	31 0.58	31 0.00	31 0.58	31 0.58	32 1.00	31 0.58	32 1.15	32 0.58	31 0.58	

Data arranged as: Mean
Standard deviation

APPENDICES

APPENDIX A

Clinical Chemistry Data

CLINICAL CHEMISTRY DATA

EXPLANATORY NOTES

ABBREVIATIONS:

CHOL - cholesterol
TRIG - triglycerides
HDL high-density lipoprotein cholesterol
non-HDL non-high-density lipoprotein cholesterol
PBS - phosphate buffered saline

H-24921, H-26313, and H-26225:

Evaluation of the Interference of the Test Substances in the Analysis of Rat Serum Lipids

DuPont-15372

Clinical Chemistry Data for H-24921 in PBS

CHOL (mg/dL)

Negative

Run	Control	720 $\mu\text{g/mL}$	360 $\mu\text{g/mL}$	180 $\mu\text{g/mL}$	90 $\mu\text{g/mL}$	45 $\mu\text{g/mL}$	22.5 $\mu\text{g/mL}$	11.3 $\mu\text{g/mL}$	5.6 $\mu\text{g/mL}$	2.8 $\mu\text{g/mL}$	1.4 $\mu\text{g/mL}$	0.7 $\mu\text{g/mL}$
1	0	0	0	0	0	0	0	0	0	0	0	0
2	0	0	0	0	0	0	0	0	0	0	0	0
3	0	0	0	0	0	0	0	0	0	0	0	0

TRIG (mg/dL)

Negative

Run	Control	720 $\mu\text{g/mL}$	360 $\mu\text{g/mL}$	180 $\mu\text{g/mL}$	90 $\mu\text{g/mL}$	45 $\mu\text{g/mL}$	22.5 $\mu\text{g/mL}$	11.3 $\mu\text{g/mL}$	5.6 $\mu\text{g/mL}$	2.8 $\mu\text{g/mL}$	1.4 $\mu\text{g/mL}$	0.7 $\mu\text{g/mL}$
1	0	0	0	0	0	0	0	0	0	0	0	0
2	0	0	0	0	0	0	0	0	0	0	0	0
3	0	0	0	0	0	0	0	0	0	0	0	0

HDL (mg/dL)

Negative

Run	Control	720 $\mu\text{g/mL}$	360 $\mu\text{g/mL}$	180 $\mu\text{g/mL}$	90 $\mu\text{g/mL}$	45 $\mu\text{g/mL}$	22.5 $\mu\text{g/mL}$	11.3 $\mu\text{g/mL}$	5.6 $\mu\text{g/mL}$	2.8 $\mu\text{g/mL}$	1.4 $\mu\text{g/mL}$	0.7 $\mu\text{g/mL}$
1	0	0	0	0	0	0	0	0	0	0	0	0
2	0	0	0	0	0	0	0	0	0	0	0	0
3	0	0	0	0	0	0	0	0	0	0	0	0

non-HDL (mg/dL)

Negative

Run	Control	720 $\mu\text{g/mL}$	360 $\mu\text{g/mL}$	180 $\mu\text{g/mL}$	90 $\mu\text{g/mL}$	45 $\mu\text{g/mL}$	22.5 $\mu\text{g/mL}$	11.3 $\mu\text{g/mL}$	5.6 $\mu\text{g/mL}$	2.8 $\mu\text{g/mL}$	1.4 $\mu\text{g/mL}$	0.7 $\mu\text{g/mL}$
1	0	0	0	0	0	0	0	0	0	0	0	0
2	0	0	0	0	0	0	0	0	0	0	0	0
3	0	0	0	0	0	0	0	0	0	0	0	0

H-24921, H-26313, and H-26225:
Evaluation of the Interference of the Test Substances in the Analysis of Rat Serum Lipids

DuPont-15372

Clinical Chemistry Data for H-24921 in Serum

CHOL (mg/dL)

Negative												
Run	Control	720 $\mu\text{g/mL}$	360 $\mu\text{g/mL}$	180 $\mu\text{g/mL}$	90 $\mu\text{g/mL}$	45 $\mu\text{g/mL}$	22.5 $\mu\text{g/mL}$	11.3 $\mu\text{g/mL}$	5.6 $\mu\text{g/mL}$	2.8 $\mu\text{g/mL}$	1.4 $\mu\text{g/mL}$	0.7 $\mu\text{g/mL}$
1	54	52	52	53	54	54	53	60	55	54	54	54
2	54	51	53	53	54	55	57	56	56	54	54	55
3	54	51	53	53	54	54	55	54	54	54	54	53

TRIG (mg/dL)

Negative												
Run	Control	720 $\mu\text{g/mL}$	360 $\mu\text{g/mL}$	180 $\mu\text{g/mL}$	90 $\mu\text{g/mL}$	45 $\mu\text{g/mL}$	22.5 $\mu\text{g/mL}$	11.3 $\mu\text{g/mL}$	5.6 $\mu\text{g/mL}$	2.8 $\mu\text{g/mL}$	1.4 $\mu\text{g/mL}$	0.7 $\mu\text{g/mL}$
1	49	47	47	49	49	49	48	49	48	49	49	49
2	48	46	48	48	49	49	51	50	50	49	49	50
3	48	46	48	49	49	49	50	49	49	49	49	49

HDL (mg/dL)

Negative												
Run	Control	720 $\mu\text{g/mL}$	360 $\mu\text{g/mL}$	180 $\mu\text{g/mL}$	90 $\mu\text{g/mL}$	45 $\mu\text{g/mL}$	22.5 $\mu\text{g/mL}$	11.3 $\mu\text{g/mL}$	5.6 $\mu\text{g/mL}$	2.8 $\mu\text{g/mL}$	1.4 $\mu\text{g/mL}$	0.7 $\mu\text{g/mL}$
1	24	21	22	23	23	23	22	23	23	23	23	23
2	23	21	22	22	23	23	25	24	24	24	23	24
3	23	21	22	23	23	23	24	23	23	23	24	23

non-HDL (mg/dL)

Negative												
Run	Control	720 $\mu\text{g/mL}$	360 $\mu\text{g/mL}$	180 $\mu\text{g/mL}$	90 $\mu\text{g/mL}$	45 $\mu\text{g/mL}$	22.5 $\mu\text{g/mL}$	11.3 $\mu\text{g/mL}$	5.6 $\mu\text{g/mL}$	2.8 $\mu\text{g/mL}$	1.4 $\mu\text{g/mL}$	0.7 $\mu\text{g/mL}$
1	30	31	31	30	31	31	31	37	32	31	31	31
2	31	30	31	31	31	32	32	32	32	30	31	31
3	31	30	30	30	31	31	31	31	31	31	30	30

Clinical Chemistry Data for H-26313 in PBS

CHOL (mg/dL)

Negative		720 $\mu\text{g/mL}$	360 $\mu\text{g/mL}$	180 $\mu\text{g/mL}$	90 $\mu\text{g/mL}$	45 $\mu\text{g/mL}$	22.5 $\mu\text{g/mL}$	11.3 $\mu\text{g/mL}$	5.6 $\mu\text{g/mL}$	2.8 $\mu\text{g/mL}$	1.4 $\mu\text{g/mL}$	0.7 $\mu\text{g/mL}$
Run	Control	0	0	0	0	0	0	0	0	0	0	0
1		0	0	0	0	0	0	0	0	0	0	0
2		0	0	0	0	0	0	0	0	0	0	0
3		0	0	0	0	0	0	0	0	0	0	0

TRIG (mg/dL)

Negative		720 $\mu\text{g/mL}$	360 $\mu\text{g/mL}$	180 $\mu\text{g/mL}$	90 $\mu\text{g/mL}$	45 $\mu\text{g/mL}$	22.5 $\mu\text{g/mL}$	11.3 $\mu\text{g/mL}$	5.6 $\mu\text{g/mL}$	2.8 $\mu\text{g/mL}$	1.4 $\mu\text{g/mL}$	0.7 $\mu\text{g/mL}$
Run	Control	0	0	0	0	0	0	0	0	0	0	0
1		0	0	0	0	0	0	0	0	0	0	0
2		0	0	0	0	0	0	0	0	0	0	0
3		0	0	0	0	0	0	0	0	0	0	0

HDL (mg/dL)

Negative		720 $\mu\text{g/mL}$	360 $\mu\text{g/mL}$	180 $\mu\text{g/mL}$	90 $\mu\text{g/mL}$	45 $\mu\text{g/mL}$	22.5 $\mu\text{g/mL}$	11.3 $\mu\text{g/mL}$	5.6 $\mu\text{g/mL}$	2.8 $\mu\text{g/mL}$	1.4 $\mu\text{g/mL}$	0.7 $\mu\text{g/mL}$
Run	Control	0	0	0	0	0	0	0	0	0	0	0
1		0	0	0	0	0	0	0	0	0	0	0
2		0	0	0	0	0	0	0	0	0	0	0
3		0	0	0	0	0	0	0	0	0	0	0

non-HDL (mg/dL)

Negative		720 $\mu\text{g/mL}$	360 $\mu\text{g/mL}$	180 $\mu\text{g/mL}$	90 $\mu\text{g/mL}$	45 $\mu\text{g/mL}$	22.5 $\mu\text{g/mL}$	11.3 $\mu\text{g/mL}$	5.6 $\mu\text{g/mL}$	2.8 $\mu\text{g/mL}$	1.4 $\mu\text{g/mL}$	0.7 $\mu\text{g/mL}$
Run	Control	0	0	0	0	0	0	0	0	0	0	0
1		0	0	0	0	0	0	0	0	0	0	0
2		0	0	0	0	0	0	0	0	0	0	0
3		0	0	0	0	0	0	0	0	0	0	0

Clinical Chemistry Data for H-26313 in Serum

CHOL (mg/dL)

Negative

Run	Control	720 $\mu\text{g/mL}$	360 $\mu\text{g/mL}$	180 $\mu\text{g/mL}$	90 $\mu\text{g/mL}$	45 $\mu\text{g/mL}$	22.5 $\mu\text{g/mL}$	11.3 $\mu\text{g/mL}$	5.6 $\mu\text{g/mL}$	2.8 $\mu\text{g/mL}$	1.4 $\mu\text{g/mL}$	0.7 $\mu\text{g/mL}$
1	54	51	53	54	54	55	55	55	55	55	54	53
2	54	52	53	53	55	56	56	54	57	55	54	57
3	54	52	53	54	54	53	55	55	55	55	54	56

TRIG (mg/dL)

Negative

Run	Control	720 $\mu\text{g/mL}$	360 $\mu\text{g/mL}$	180 $\mu\text{g/mL}$	90 $\mu\text{g/mL}$	45 $\mu\text{g/mL}$	22.5 $\mu\text{g/mL}$	11.3 $\mu\text{g/mL}$	5.6 $\mu\text{g/mL}$	2.8 $\mu\text{g/mL}$	1.4 $\mu\text{g/mL}$	0.7 $\mu\text{g/mL}$
1	48	46	48	48	49	48	47	49	49	49	49	49
2	49	47	48	48	49	50	50	49	50	49	49	51
3	49	47	48	48	48	49	50	49	49	50	50	51

HDL (mg/dL)

Negative

Run	Control	720 $\mu\text{g/mL}$	360 $\mu\text{g/mL}$	180 $\mu\text{g/mL}$	90 $\mu\text{g/mL}$	45 $\mu\text{g/mL}$	22.5 $\mu\text{g/mL}$	11.3 $\mu\text{g/mL}$	5.6 $\mu\text{g/mL}$	2.8 $\mu\text{g/mL}$	1.4 $\mu\text{g/mL}$	0.7 $\mu\text{g/mL}$
1	23	21	22	23	23	23	23	23	23	23	23	23
2	24	21	22	23	23	24	24	23	24	23	23	24
3	23	21	22	23	23	23	24	24	23	24	23	24

non-HDL (mg/dL)

Negative

Run	Control	720 $\mu\text{g/mL}$	360 $\mu\text{g/mL}$	180 $\mu\text{g/mL}$	90 $\mu\text{g/mL}$	45 $\mu\text{g/mL}$	22.5 $\mu\text{g/mL}$	11.3 $\mu\text{g/mL}$	5.6 $\mu\text{g/mL}$	2.8 $\mu\text{g/mL}$	1.4 $\mu\text{g/mL}$	0.7 $\mu\text{g/mL}$
1	31	30	31	31	31	32	32	32	32	32	31	30
2	30	31	31	30	32	32	32	31	33	32	31	33
3	31	31	31	31	31	30	31	31	32	31	31	32

H-24921, H-26313, and H-26225:

Evaluation of the Interference of the Test Substances in the Analysis of Rat Serum Lipids

DuPont-15372

Clinical Chemistry Data for H-26225 in PBS

CHOL (mg/dL)																							
Negative																							
Run	Control	720	μg/mL	360	μg/mL	180	μg/mL	90	μg/mL	45	μg/mL	22.5	μg/mL	11.3	μg/mL	5.6	μg/mL	2.8	μg/mL	1.4	μg/mL	0.7	μg/mL
1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
TRIG (mg/dL)																							
Negative																							
Run	Control	720	μg/mL	360	μg/mL	180	μg/mL	90	μg/mL	45	μg/mL	22.5	μg/mL	11.3	μg/mL	5.6	μg/mL	2.8	μg/mL	1.4	μg/mL	0.7	μg/mL
1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
HDL (mg/dL)																							
Negative																							
Run	Control	720	μg/mL	360	μg/mL	180	μg/mL	90	μg/mL	45	μg/mL	22.5	μg/mL	11.3	μg/mL	5.6	μg/mL	2.8	μg/mL	1.4	μg/mL	0.7	μg/mL
1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
non-HDL (mg/dL)																							
Negative																							
Run	Control	720	μg/mL	360	μg/mL	180	μg/mL	90	μg/mL	45	μg/mL	22.5	μg/mL	11.3	μg/mL	5.6	μg/mL	2.8	μg/mL	1.4	μg/mL	0.7	μg/mL
1	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
2	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	
3	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	0	

Company Sanitized. Does not contain TSCA CBI

H-24921, H-26313, and H-26225:

Evaluation of the Interference of the Test Substances in the Analysis of Rat Serum Lipids

DuPont-15372

Clinical Chemistry Data for H-26225 in Serum

CHOL (mg/dL)

Negative

Run	Control	720 $\mu\text{g/mL}$	360 $\mu\text{g/mL}$	180 $\mu\text{g/mL}$	90 $\mu\text{g/mL}$	45 $\mu\text{g/mL}$	22.5 $\mu\text{g/mL}$	11.3 $\mu\text{g/mL}$	5.6 $\mu\text{g/mL}$	2.8 $\mu\text{g/mL}$	1.4 $\mu\text{g/mL}$	0.7 $\mu\text{g/mL}$
1	54	51	53	53	54	54	54	56	54	54	55	54
2	54	52	53	54	54	55	54	56	54	56	54	54
3	54	51	53	54	54	54	55	54	55	54	54	55

TRIG (mg/dL)

Negative

Run	Control	720 $\mu\text{g/mL}$	360 $\mu\text{g/mL}$	180 $\mu\text{g/mL}$	90 $\mu\text{g/mL}$	45 $\mu\text{g/mL}$	22.5 $\mu\text{g/mL}$	11.3 $\mu\text{g/mL}$	5.6 $\mu\text{g/mL}$	2.8 $\mu\text{g/mL}$	1.4 $\mu\text{g/mL}$	0.7 $\mu\text{g/mL}$
1	49	47	47	48	49	48	49	49	49	49	49	49
2	49	47	48	49	49	49	49	50	49	50	49	49
3	49	47	48	49	48	49	49	48	49	50	49	49

HDL (mg/dL)

Negative

Run	Control	720 $\mu\text{g/mL}$	360 $\mu\text{g/mL}$	180 $\mu\text{g/mL}$	90 $\mu\text{g/mL}$	45 $\mu\text{g/mL}$	22.5 $\mu\text{g/mL}$	11.3 $\mu\text{g/mL}$	5.6 $\mu\text{g/mL}$	2.8 $\mu\text{g/mL}$	1.4 $\mu\text{g/mL}$	0.7 $\mu\text{g/mL}$
1	23	21	22	23	23	23	23	23	23	23	23	23
2	23	21	22	23	23	23	23	24	23	23	22	23
3	23	20	22	23	23	23	23	23	23	23	23	23

non-HDL (mg/dL)

Negative

Run	Control	720 $\mu\text{g/mL}$	360 $\mu\text{g/mL}$	180 $\mu\text{g/mL}$	90 $\mu\text{g/mL}$	45 $\mu\text{g/mL}$	22.5 $\mu\text{g/mL}$	11.3 $\mu\text{g/mL}$	5.6 $\mu\text{g/mL}$	2.8 $\mu\text{g/mL}$	1.4 $\mu\text{g/mL}$	0.7 $\mu\text{g/mL}$
1	31	30	31	30	31	31	31	33	31	31	32	31
2	31	31	31	31	31	32	31	32	31	33	31	31
3	31	31	31	31	31	31	32	31	32	31	32	32